pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ahzantive
drug · protein
save

aflibercept biosimilar

Marketedupdated 6mo ago
by Sam Chun Dang Pharm Co Ltd🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 7
  • tagApproval20 co-mentions · 10 sources
  • drugEYLEA HD17 co-mentions · 10 sources
  • drugEylea15 co-mentions · 10 sources
  • drugYESAFILI9 co-mentions · 7 sources
  • drugENZEEVU6 co-mentions · 3 sources
  • companySandoz Inc3 co-mentions · 3 sources
  • companyBiocon Biologics Ltd2 co-mentions · 2 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 16 approved and 39 investigational indications.

indications

investigational
Diabetic Macular Edema

targets

Placenta growth factorVascular endothelial growth factor A, long form

all catalysts(3)

approval · 3
Aug 9, 2024
approval
2y ago
ENZEEVU (AFLIBERCEPT-ABZV) — FDA approval
aflibercept biosimilar
→
Feb 10, 2025
approval
2y ago
ENZEEVU (AFLIBERCEPT-ABZV) — FDA approval
aflibercept biosimilar
→
Feb 12, 2026
approval
9mo ago
ENZEEVU (AFLIBERCEPT-ABZV) — FDA approval
aflibercept biosimilar
→

Trials studying aflibercept biosimilar

  • phase3Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degenerationcompletedn=434
  • phase3Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)completedn=413
  • phase3A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)completedn=449

News(10)

  • Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
    AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.
    biopharma_dive · 13d ago
  • Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
    Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…
    biospace · 16d ago
  • EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
    EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shiftin…
    biospace · 27d ago
  • This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
    The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
    biopharma_dive · 1mo ago
  • Lilly, Foghorn part ways; Wave’s FDA-approved plans
    The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
    biopharma_dive · 1mo ago
  • Kodiak skyrockets on positive study data for 2 eye drugs
    The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
    biopharma_dive · 1mo ago
  • Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
    Kodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet a…
    endpoints · 1mo ago
  • Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
    Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
    biospace · 1mo ago
  • STAT+: AbbVie wins FDA nod for Parkinson’s pill
    The FDA has approved AbbVie’s once-daily Parkinson’s pill for sales, based on a late-stage study that showed the drug helped improve symptoms.
    stat · 1mo ago
  • Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
    Two of Kodiak Sciences’ drug candidates have matched aflibercept in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year.
    fiercebiotech · 1mo ago
view all news mentions →
brand
Ahzantive
trade names
Eylea, Yesafili, Zaltrap
generic
aflibercept-abzv
MOA
Placenta growth factor inhibitor; Vascular endothelial growth factor A inhibitor
indication
Diabetic Macular Edema
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 37m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?